Dyadic International Inc. (DYAI) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Company: Dyadic International, Inc.
Reporting Period: Quarter ended March 31, 2025
Business Model: Global biotechnology platform company developing microbial protein production platforms (C1 for pharmaceuticals; Dapibus™ for non-pharmaceutical applications). The company generates revenue through research collaborations, government grants, and sublicensing agreements. It operates as a single segment with offices in the U.S. and the Netherlands.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenue | $393,572 | $334,617 |
| Net Loss | $(2,027,579) | $(2,009,596) |
| Loss Per Share (Basic/Diluted) | $(0.07) | $(0.07) |
| Cash & Cash Equivalents | $5,064,941 | $10,569,814 |
| Total Liquidity (Cash + Investments) | $7,349,413 | $13,326,391 |
| Convertible Notes Outstanding (Principal) | $5,090,000 | $6,000,000 |
| Stockholders' Equity | $923,611 | $4,515,802 |
Material Changes vs. Prior Period
- Revenue Composition: Total revenue increased by 17.6% year-over-year, driven primarily by $210,472 in new grant revenue (Gates Foundation and CEPI). Conversely, research and development revenue from collaborations decreased from $334,617 to $183,100 due to fewer active collaborations.
- Operating Expenses: General and Administrative (G&A) expenses decreased by 10.8% to $1.60 million, attributed to reductions in business development, management incentives, and legal fees. R&D expenses decreased slightly to $495,000.
- Other Income/Expense: Net other income turned to a net expense of $(25,104) compared to income of $115,962 in Q1 2024. This shift was caused by increased interest expense on Convertible Notes and the absence of the $60,977 gain on the sale of Alphazyme recorded in the prior year.
- Liquidity: Cash and cash equivalents declined by approximately $1.44 million during the quarter, primarily due to net cash used in operating activities of $1.95 million.
Guidance, Outlook, and Risks
- Commercialization Targets: Management anticipates commercialization of functional recombinant products in 2025, including Human Serum Albumin (Q3 2025) and dairy enzymes (late 2025). Sampling initiatives for Transferrin and Growth Factors are expected in Q2 2025.
- Grant Funding: The company secured a $4.5 million grant from CEPI (Dyadic to receive up to $2.4 million) and continues a $3.1 million project with the Gates Foundation for monoclonal antibody development.
- Debt Amendments: On May 1, 2025, the company amended its Convertible Notes, moving the Redemption Date to December 1, 2026. The conversion price remains $1.40 per share.
- Liquidity Outlook: Management believes existing cash and investments ($7.35 million) are sufficient to meet operational requirements for at least the next 12 months. However, the company expects to continue incurring losses and may need to raise additional capital, which could be dilutive.
- Risks: Key risks include the history of net losses, reliance on third-party CROs, regulatory acceptance of microbial protein platforms, and the ability to commercialize technologies. The company maintains a 100% valuation allowance on deferred tax assets due to operating losses.
Investor Verification Checklist
- Grant Revenue Recognition: Verify the timing and conditions for recognizing the $210k in Q1 grant revenue from Gates Foundation and CEPI, as this is a new revenue stream compared to prior periods.
- Convertible Note Terms: Confirm the impact of the May 2025 amendment on the redemption date (Dec 1, 2026) and the conversion price ($1.40) on potential future dilution.
- Customer Concentration: Note that four customers accounted for 89% of Q1 2025 revenue; assess the risk of losing these key collaborators.
- Commercialization Timeline: Monitor progress on the Q3 2025 launch of Human Serum Albumin and late 2025 dairy enzyme launches to validate revenue projections.
- Cash Burn Rate: Track the quarterly cash burn (approx. $2.0M operating cash outflow) against the $7.35M liquidity runway to determine the urgency of future capital raises.